The FDA Decision Most Biotech Founders Get Backward
Most biotech founders pick their regulatory pathway the way tourists pick a restaurant. They look at what worked for someone else, they hope it fits, and they find out three years and several million dollars later that it doesn’t.
I run two companies inside CBER’s jurisdiction right now. One moves biologics through the 351(a) pathway. The other moves a device through a different clock entirely. I have watched founders in both worlds make the same mistake, and it is not a science mistake. It is a sequencing mistake.
Here is the uncomfortable part. The regulatory pathway is not paperwork you handle after the science works. It is a decision that determines whether the science gets a chance to work at all, on a timeline your investors will still be alive for.
The mistake happens before the first experiment
Founders treat FDA strategy as a downstream task. Build the product, run some preclinical work, then hire regulatory counsel to figure out the filing. That order feels intuitive. It is also backward.
Classification decides everything that follows it. A cell or tissue product regulated under 21 CFR 1271 as a 361 HCT/P faces a different evidentiary bar than the same biological concept regulated under 351(a) as a biologic requiring an IND and a BLA. The line between those two depends on manufacturing detail: degree of manipulation, homologous use, combination with another article. Get the classification wrong early and you do not get a warning letter. You get a company that spent two years building toward a pathway that was never available to it.
The founders who survive this are the ones who ask the classification question before they finalize a manufacturing process, not after.
RMAT is not a nice-to-have. It is a timeline decision.
The Regenerative Medicine Advanced Therapy designation exists to compress the distance between a promising early signal and an approved product. As of the most recent public tracking, roughly 131 RMAT designations have been granted since the pathway launched under the 21st Century Cures Act (The Niche). That number is small relative to the volume of cell and gene therapy programs in development. Most sponsors never apply. Some apply too late, after the trial design is locked and the preliminary clinical evidence can no longer be shaped to meet the bar.
RMAT gets you rolling review, more frequent FDA interaction, and potential eligibility for accelerated approval. Every one of those benefits requires you to ask for the designation while your development plan is still flexible. Founders who wait until Phase 2 to think about RMAT have already priced themselves out of the fastest version of their own program.
The capital math nobody says out loud
The median cost to bring a new drug to market sits close to a billion dollars, and older estimates that include the full cost of failure run past two and a half billion when capitalized development costs are counted (BioSpace; Applied Clinical Trials). Biologics do not get a discount on that math. Every year added to your regulatory timeline is a year of burn your cap table has to absorb, and every wrong pathway decision adds years, not months.
Get Andrew Jonathan Hillman’s stories in your inbox
Join Medium for free to get updates from this writer.
Investors do not fund science. They fund a probability-weighted timeline to an approved product. A founder who cannot state their classification rationale, their RMAT strategy, and their pre-IND meeting plan in the first slide of a pitch deck is asking investors to underwrite a guess.
Three questions before you file anything
Ask these before you write a protocol, not after.
First, what is the precise regulatory classification of your product, and what manufacturing decision determines whether that classification holds. If you cannot answer this in one sentence, you do not have a regulatory strategy. You have a hope.
Second, does your indication and mechanism make you a credible RMAT candidate, and if so, what is the earliest point in development where you can request it. The designation rewards sponsors who show up early with a plausible mechanism and a serious unmet need, not sponsors who show up late with a completed trial looking for a badge.
Third, what does your Pre-IND Type B meeting need to accomplish for FDA to agree with your development plan instead of merely tolerating it. A pre-IND meeting is not a formality. It is the moment you find out whether the agency will fight you for the next five years or work with you.
The pathway is the product
Founders fall in love with the science and treat the regulatory strategy as a compliance function. Flip that. The pathway you choose determines your capital requirements, your timeline, your trial design, and whether your science ever reaches a patient. Get the classification and the designation strategy right at the start, and every decision after that gets easier. Get it wrong, and no amount of good science fixes a pathway you never should have chosen.
The founders who win in this industry are not always the ones with the best molecule or the best device. They are the ones who understood, before they spent a dollar, exactly what door they were walking through.
Sources:
